MS4A1 and B-cell non-Hodgkin lymphoma: In 1997, rituximab (chimeric mouse/human IgG1 monoclonal antibody directed against the extracellular loop of CD20) was approved for treatment of B-NHL, particularly relevant as most B-cell NHL express CD20 [54].